Search

Searching with a thematic focus on Trade Policy, Intellectual Property Rights

Showing 221-230 of 420 results

Pages

• Document

  Post-Doha African challenges in the Sanitary and Phytosanitary and Trade Related Intellectual Property Rights Agreement

  Kenya Institute for Public Policy Research and Analysis, 2002

  Africa's capacity to negotiate at the international level within organisations like the WTO has been greatly improved since Uruguay.
• Document

  Copyright and the Web

  Commonwealth of Learning, 2003

  Report of a Virtual Conference on Copyright was held from February 10 to 28, 2003. The 550 participants posted approximately 600 messages during the Conference.
• Document

  Losing livestock, losing livelihoods

  Program on Peacekeeping Policy, Institute of Public Policy, 2003

  This article examines the reasons for the ongoing decline in the biological diversity of domestic livestock species and discusses the potential impacts on food security. The author argues the importance of preserving local breeds that are well adapted to environmental conditions and the needs of local people whilst also providing a valuable gene pool for the development of new commercial species.
• Document

  Indicators of the relative importance of IPRs in developing countries

  Queen Elizabeth House Library, University of Oxford, 2002

  This paper focuses on the long term structural issues concerning the impact of TRIPS on industrial and technology development in poor countries and seeks to indicate the potential significance of IPRs by differentiating developing countries according to the expected impact of stronger protection.The paper first notes the key potential impacts of TRIPS with the authors concluding that that, whil
• Document

  India's plant variety and farmers' rights legislation: potential impact on stakeholder access to genetic resources

  International Food Policy Research Institute, 2003

  This paper explores the possible implications of establishing IPR regimes that simultaneously try to protect the rights of breeders and farmers on the utilisation and exchange of genetic resources posing the question “Could the attempt to distribute ownership rights to various stakeholders pose the threat of an anti-commons, where resources are under utilised due to multiple ownership?”The aut
• Document

  Genetic inventions, intellectual property rights and licensing practices

  Organisation for Economic Co-operation and Development, 2002

  This publication is an edited and amplified version of the rapporteur’s report of the Working Party on Biotechnology expert workshop, “Genetic Inventions, IPR, and Licensing Practices”, held in Berlin in January 2002.
• Document

  Globalization and access to drugs

  World Health Organization, 1999

  Debates over affordability and innovation have become perhaps the most contentious in the area of national medicines policies.
• Document

  Implications of the Doha Declaration on the TRIPS Agreement and public health

  Essential Drugs and Medicine Policy, WHO, 2002

  The special declaration on issues relating to the Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) represents an unprecedented step for the World Trade Organisation (WTO), but what are its implications?
• Document

  Health (and IPRs)

  Commission on Intellectual Property Rights, 2002

  It is feared that stronger patent protection is likely to increase the costs of medicines and reduce the ability of the poorest developing countries to improve public health conditions among their populations. Yet for pharmaceutical companies, patent protection gives them incentives to conduct research and development into new drugs.
• Document

  Report to the Prime Minister of the UK Working Group on Increasing Access to Essential Medicines in the Developing World: policy recommendations and strategy

  Department for International Development, UK, 2002

  At the G8 Summit in Genoa in 2001, the UK Prime Minister announced his intention to establish a high-level working group on increasing access to essential medicines in the developing world. The Working Group brought together senior representatives from the UK pharmaceutical industry, the UN, EC, Foundations and UK Ministers from Health, Trade, and Treasury.

Pages